Fortis Healthcare Limited
Fortis Healthcare Limited (FORTIS.NS) Stock Competitors & Peer Comparison
See (FORTIS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FORTIS.NS | ₹974.60 | +1.46% | 735.8B | 76.62 | ₹12.72 | +0.10% |
| APOLLOHOSP.BO | ₹8,098.65 | +0.91% | 1.2T | 64.68 | ₹125.21 | +0.25% |
| APOLLOHOSP.NS | ₹8,078.50 | +0.65% | 1.2T | 64.52 | ₹125.21 | +0.25% |
| MAXHEALTH.BO | ₹1,076.30 | +0.89% | 1T | 74.18 | ₹14.51 | +0.14% |
| MAXHEALTH.NS | ₹1,075.70 | +0.65% | 1T | 74.03 | ₹14.53 | +0.14% |
| FORTIS.BO | ₹974.00 | +1.45% | 735.3B | 76.63 | ₹12.71 | +0.10% |
| ASTERDM.NS | ₹764.85 | +2.13% | 395.4B | 119.32 | ₹6.41 | +0.53% |
| ASTERDM.BO | ₹764.20 | +2.10% | 395B | 119.22 | ₹6.41 | +0.53% |
| NH.BO | ₹1,903.05 | +1.05% | 386.5B | 45.79 | ₹41.56 | +0.24% |
| NH.NS | ₹1,902.40 | +0.97% | 386.4B | 49.68 | ₹38.29 | +0.24% |
Stock Comparison
FORTIS.NS vs APOLLOHOSP.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, APOLLOHOSP.BO has a market cap of 1.2T. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while APOLLOHOSP.BO trades at ₹8,098.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas APOLLOHOSP.BO's P/E ratio is 64.68. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is less volatile compared to APOLLOHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check APOLLOHOSP.BO's competition here
FORTIS.NS vs APOLLOHOSP.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, APOLLOHOSP.NS has a market cap of 1.2T. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while APOLLOHOSP.NS trades at ₹8,078.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas APOLLOHOSP.NS's P/E ratio is 64.52. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is less volatile compared to APOLLOHOSP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check APOLLOHOSP.NS's competition here
FORTIS.NS vs MAXHEALTH.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MAXHEALTH.BO has a market cap of 1T. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MAXHEALTH.BO trades at ₹1,076.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MAXHEALTH.BO's P/E ratio is 74.18. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXHEALTH.BO's competition here
FORTIS.NS vs MAXHEALTH.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MAXHEALTH.NS has a market cap of 1T. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MAXHEALTH.NS trades at ₹1,075.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MAXHEALTH.NS's P/E ratio is 74.03. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXHEALTH.NS's competition here
FORTIS.NS vs FORTIS.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, FORTIS.BO has a market cap of 735.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while FORTIS.BO trades at ₹974.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas FORTIS.BO's P/E ratio is 76.63. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to FORTIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check FORTIS.BO's competition here
FORTIS.NS vs ASTERDM.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ASTERDM.NS has a market cap of 395.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ASTERDM.NS trades at ₹764.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ASTERDM.NS's P/E ratio is 119.32. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASTERDM.NS's ROE of +0.10%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASTERDM.NS's competition here
FORTIS.NS vs ASTERDM.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ASTERDM.BO has a market cap of 395B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ASTERDM.BO trades at ₹764.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ASTERDM.BO's P/E ratio is 119.22. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASTERDM.BO's ROE of +0.10%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASTERDM.BO's competition here
FORTIS.NS vs NH.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, NH.BO has a market cap of 386.5B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while NH.BO trades at ₹1,903.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas NH.BO's P/E ratio is 45.79. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is less volatile compared to NH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check NH.BO's competition here
FORTIS.NS vs NH.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, NH.NS has a market cap of 386.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while NH.NS trades at ₹1,902.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas NH.NS's P/E ratio is 49.68. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is less volatile compared to NH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check NH.NS's competition here
FORTIS.NS vs MEDANTA.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MEDANTA.BO has a market cap of 333.5B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MEDANTA.BO trades at ₹1,241.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MEDANTA.BO's P/E ratio is 59.96. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDANTA.BO's competition here
FORTIS.NS vs MEDANTA.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MEDANTA.NS has a market cap of 333.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MEDANTA.NS trades at ₹1,240.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MEDANTA.NS's P/E ratio is 59.94. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDANTA.NS's competition here
FORTIS.NS vs KIMS.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KIMS.NS has a market cap of 302.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KIMS.NS trades at ₹755.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KIMS.NS's P/E ratio is 125.97. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KIMS.NS's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KIMS.NS's competition here
FORTIS.NS vs KIMS.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KIMS.BO has a market cap of 302.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KIMS.BO trades at ₹755.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KIMS.BO's P/E ratio is 125.90. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KIMS.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KIMS.BO's competition here
FORTIS.NS vs RAINBOW.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, RAINBOW.BO has a market cap of 137.1B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while RAINBOW.BO trades at ₹1,350.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas RAINBOW.BO's P/E ratio is 53.41. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, FORTIS.NS is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check RAINBOW.BO's competition here
FORTIS.NS vs RAINBOW.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, RAINBOW.NS has a market cap of 136.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while RAINBOW.NS trades at ₹1,342.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas RAINBOW.NS's P/E ratio is 53.11. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, FORTIS.NS is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check RAINBOW.NS's competition here
FORTIS.NS vs HCG.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, HCG.NS has a market cap of 97.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while HCG.NS trades at ₹652.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas HCG.NS's P/E ratio is 672.22. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is less volatile compared to HCG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check HCG.NS's competition here
FORTIS.NS vs HCG.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, HCG.BO has a market cap of 97.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while HCG.BO trades at ₹651.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas HCG.BO's P/E ratio is 671.96. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is less volatile compared to HCG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check HCG.BO's competition here
FORTIS.NS vs JLHL.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, JLHL.NS has a market cap of 86.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while JLHL.NS trades at ₹1,318.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas JLHL.NS's P/E ratio is 44.68. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, FORTIS.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check JLHL.NS's competition here
FORTIS.NS vs JLHL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, JLHL.BO has a market cap of 86.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while JLHL.BO trades at ₹1,318.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas JLHL.BO's P/E ratio is 44.66. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, FORTIS.NS is more volatile compared to JLHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check JLHL.BO's competition here
FORTIS.NS vs YATHARTH.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, YATHARTH.BO has a market cap of 81.7B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while YATHARTH.BO trades at ₹847.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas YATHARTH.BO's P/E ratio is 48.76. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check YATHARTH.BO's competition here
FORTIS.NS vs YATHARTH.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, YATHARTH.NS has a market cap of 81.6B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while YATHARTH.NS trades at ₹846.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas YATHARTH.NS's P/E ratio is 48.64. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check YATHARTH.NS's competition here
FORTIS.NS vs KOVAI.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KOVAI.NS has a market cap of 73B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KOVAI.NS trades at ₹5,339.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KOVAI.NS's P/E ratio is 24.80. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, FORTIS.NS is more volatile compared to KOVAI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check KOVAI.NS's competition here
FORTIS.NS vs KOVAI.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KOVAI.BO has a market cap of 58.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KOVAI.BO trades at ₹5,339.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KOVAI.BO's P/E ratio is 24.78. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, FORTIS.NS is less volatile compared to KOVAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KOVAI.BO's competition here
FORTIS.NS vs ARTEMISMED.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ARTEMISMED.BO has a market cap of 44.2B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ARTEMISMED.BO trades at ₹279.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ARTEMISMED.BO's ROE of +0.12%. Regarding short-term risk, FORTIS.NS is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ARTEMISMED.BO's competition here
FORTIS.NS vs ARTEMISMED.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ARTEMISMED.NS has a market cap of 44.2B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ARTEMISMED.NS trades at ₹279.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ARTEMISMED.NS's P/E ratio is 122.07. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ARTEMISMED.NS's ROE of +0.12%. Regarding short-term risk, FORTIS.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ARTEMISMED.NS's competition here
FORTIS.NS vs INDRAMEDCO.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, INDRAMEDCO.BO has a market cap of 33B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while INDRAMEDCO.BO trades at ₹360.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas INDRAMEDCO.BO's P/E ratio is 18.05. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to INDRAMEDCO.BO's ROE of +0.28%. Regarding short-term risk, FORTIS.NS is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check INDRAMEDCO.BO's competition here
FORTIS.NS vs INDRAMEDCO.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, INDRAMEDCO.NS has a market cap of 33B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while INDRAMEDCO.NS trades at ₹359.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas INDRAMEDCO.NS's P/E ratio is 18.04. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to INDRAMEDCO.NS's ROE of +0.28%. Regarding short-term risk, FORTIS.NS is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check INDRAMEDCO.NS's competition here
FORTIS.NS vs DRAGARWQ.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, DRAGARWQ.BO has a market cap of 24.9B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while DRAGARWQ.BO trades at ₹5,159.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas DRAGARWQ.BO's P/E ratio is 34.92. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, FORTIS.NS is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check DRAGARWQ.BO's competition here
FORTIS.NS vs SHALBY.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, SHALBY.NS has a market cap of 17.9B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while SHALBY.NS trades at ₹166.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas SHALBY.NS's P/E ratio is 213.78. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check SHALBY.NS's competition here
FORTIS.NS vs SHALBY.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, SHALBY.BO has a market cap of 17.9B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while SHALBY.BO trades at ₹166.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas SHALBY.BO's P/E ratio is 213.78. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check SHALBY.BO's competition here
FORTIS.NS vs KMCSHIL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KMCSHIL.BO has a market cap of 15.4B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KMCSHIL.BO trades at ₹94.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KMCSHIL.BO's P/E ratio is 42.12. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KMCSHIL.BO's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KMCSHIL.BO's competition here
FORTIS.NS vs GPTHEALTH.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, GPTHEALTH.NS has a market cap of 11.6B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while GPTHEALTH.NS trades at ₹141.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas GPTHEALTH.NS's P/E ratio is 28.73. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to GPTHEALTH.NS's ROE of +0.17%. Regarding short-term risk, FORTIS.NS is less volatile compared to GPTHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check GPTHEALTH.NS's competition here
FORTIS.NS vs MAXINDIA.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXINDIA.BO's competition here
FORTIS.NS vs MAXIND.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MAXIND.NS has a market cap of 8.2B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MAXIND.NS trades at ₹155.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MAXIND.NS's P/E ratio is -5.22. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, FORTIS.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXIND.NS's competition here
FORTIS.NS vs UNIHEALTH.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, UNIHEALTH.NS has a market cap of 7.1B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while UNIHEALTH.NS trades at ₹444.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas UNIHEALTH.NS's P/E ratio is 45.22. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is less volatile compared to UNIHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check UNIHEALTH.NS's competition here
FORTIS.NS vs ASARFI.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ASARFI.BO has a market cap of 3.7B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ASARFI.BO trades at ₹187.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ASARFI.BO's P/E ratio is 22.60. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASARFI.BO's ROE of +0.13%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASARFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASARFI.BO's competition here
FORTIS.NS vs LOTUSEYE.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, LOTUSEYE.BO has a market cap of 2.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while LOTUSEYE.BO trades at ₹110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas LOTUSEYE.BO's P/E ratio is 343.75. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is more volatile compared to LOTUSEYE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check LOTUSEYE.BO's competition here
FORTIS.NS vs LOTUSEYE.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, LOTUSEYE.NS has a market cap of 2.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while LOTUSEYE.NS trades at ₹109.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas LOTUSEYE.NS's P/E ratio is 341.31. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LOTUSEYE.NS's competition here
FORTIS.NS vs MADHAVBAUG.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MADHAVBAUG.NS has a market cap of 2B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MADHAVBAUG.NS trades at ₹190.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MADHAVBAUG.NS's P/E ratio is 24.58. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is less volatile compared to MADHAVBAUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MADHAVBAUG.NS's competition here
FORTIS.NS vs LEHIL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LEHIL.BO's competition here
FORTIS.NS vs AASHKA.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, AASHKA.BO has a market cap of 1.8B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while AASHKA.BO trades at ₹78.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas AASHKA.BO's P/E ratio is 75.36. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is less volatile compared to AASHKA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check AASHKA.BO's competition here
FORTIS.NS vs JSTL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, JSTL.BO has a market cap of 1.3B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while JSTL.BO trades at ₹82.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas JSTL.BO's P/E ratio is -64.69. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, FORTIS.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check JSTL.BO's competition here
FORTIS.NS vs ASPIRA.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ASPIRA.BO has a market cap of 1.1B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ASPIRA.BO trades at ₹106.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ASPIRA.BO's P/E ratio is 77.34. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASPIRA.BO's competition here
FORTIS.NS vs FORTISMLR.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, FORTISMLR.BO has a market cap of 1B. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while FORTISMLR.BO trades at ₹53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas FORTISMLR.BO's P/E ratio is 22.16. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FORTISMLR.BO's ROE of +0.13%. Regarding short-term risk, FORTIS.NS is more volatile compared to FORTISMLR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check FORTISMLR.BO's competition here
FORTIS.NS vs MAITREYA.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MAITREYA.NS has a market cap of 947.6M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MAITREYA.NS trades at ₹174.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MAITREYA.NS's P/E ratio is 27.10. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is more volatile compared to MAITREYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MAITREYA.NS's competition here
FORTIS.NS vs SANGANI.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, SANGANI.NS has a market cap of 716.4M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while SANGANI.NS trades at ₹52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas SANGANI.NS's P/E ratio is 27.66. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is more volatile compared to SANGANI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check SANGANI.NS's competition here
FORTIS.NS vs AATMAJ.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, AATMAJ.NS has a market cap of 448.6M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while AATMAJ.NS trades at ₹19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas AATMAJ.NS's P/E ratio is 50.90. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is less volatile compared to AATMAJ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check AATMAJ.NS's competition here
FORTIS.NS vs MEDINOV.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, FORTIS.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDINOV.BO's competition here
FORTIS.NS vs NGIND.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, NGIND.BO has a market cap of 428.5M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while NGIND.BO trades at ₹127.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas NGIND.BO's P/E ratio is -30.89. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, FORTIS.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NGIND.BO's competition here
FORTIS.NS vs SML.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, SML.BO has a market cap of 311.3M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while SML.BO trades at ₹73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas SML.BO's P/E ratio is -15.60. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, FORTIS.NS is less volatile compared to SML.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check SML.BO's competition here
FORTIS.NS vs TEJNAKSH.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, TEJNAKSH.BO has a market cap of 289.5M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while TEJNAKSH.BO trades at ₹14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas TEJNAKSH.BO's P/E ratio is 20.96. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, FORTIS.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check TEJNAKSH.BO's competition here
FORTIS.NS vs CMMHOSP.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, CMMHOSP.BO has a market cap of 282.3M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while CMMHOSP.BO trades at ₹37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas CMMHOSP.BO's P/E ratio is -36.35. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, FORTIS.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check CMMHOSP.BO's competition here
FORTIS.NS vs KKSHL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, KKSHL.BO has a market cap of 265.5M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while KKSHL.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas KKSHL.BO's P/E ratio is -25.83. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check KKSHL.BO's competition here
FORTIS.NS vs NIDAN.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, NIDAN.NS has a market cap of 191.8M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while NIDAN.NS trades at ₹13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas NIDAN.NS's P/E ratio is 9.72. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is more volatile compared to NIDAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NIDAN.NS's competition here
FORTIS.NS vs FAMILYCARE.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, FAMILYCARE.BO has a market cap of 166.4M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while FAMILYCARE.BO trades at ₹3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas FAMILYCARE.BO's P/E ratio is -3.18. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, FORTIS.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check FAMILYCARE.BO's competition here
FORTIS.NS vs GLHRL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, GLHRL.BO has a market cap of 130.5M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while GLHRL.BO trades at ₹12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas GLHRL.BO's P/E ratio is -5.52. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check GLHRL.BO's competition here
FORTIS.NS vs ZDHJERK.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, ZDHJERK.BO has a market cap of 80.7M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while ZDHJERK.BO trades at ₹19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas ZDHJERK.BO's P/E ratio is 63.55. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check ZDHJERK.BO's competition here
FORTIS.NS vs GIANLIFE.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, GIANLIFE.BO has a market cap of 61.8M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while GIANLIFE.BO trades at ₹5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas GIANLIFE.BO's P/E ratio is -6.36. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, FORTIS.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check GIANLIFE.BO's competition here
FORTIS.NS vs LOOKS.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, LOOKS.BO has a market cap of 60M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while LOOKS.BO trades at ₹5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas LOOKS.BO's P/E ratio is 28.55. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LOOKS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LOOKS.BO's competition here
FORTIS.NS vs DLCL.BO Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, DLCL.BO has a market cap of 43.3M. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while DLCL.BO trades at ₹10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas DLCL.BO's P/E ratio is 12.99. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, FORTIS.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check DLCL.BO's competition here
FORTIS.NS vs NEPHROCARE-ST.NS Comparison May 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 735.8B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, FORTIS.NS is priced at ₹974.60, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 76.62, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NEPHROCARE-ST.NS's competition here